Literature DB >> 6515330

Prognostic factors in IgD myeloma: a study of 21 cases.

W E Fibbe, J Jansen.   

Abstract

A series of 21 patients with IgD myeloma was studied retrospectively, to assess which parameter present at the time of diagnosis was of prognostic importance for survival and whether the clinical staging system of Durie and Salmon had predictive value for the survival time of these patients. Survival time did not appear to be correlated with haemoglobin concentration, thrombocytopenia, initial level of M-protein, amount of Bence-Jones proteinuria, hypercalcaemia, serum creatinine level, presence of osteolytic lesions or hepatosplenomegaly. Neither did the staging system of Durie and Salmon predict the survival time. It is concluded that clinical staging is of limited value in the management and prediction of the survival time of IgD myeloma patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6515330     DOI: 10.1111/j.1600-0609.1984.tb00727.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  9 in total

Review 1.  New insights into the enigma of immunoglobulin D.

Authors:  Kang Chen; Andrea Cerutti
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

2.  IgD plasmablastic myeloma: a case report with emphasis on the cytological features.

Authors:  Mitsuaki Ishida; Keiko Hodohara; Hiroko Okuno; Miyuki Yoshii; Akiko Horinouchi; Ayaka Shirakawa; Ayumi Harada; Muneo Iwai; Keiko Yoshida; Akiko Kagotani; Takashi Yoshida; Hidetoshi Okabe
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

3.  Light chain types of IgD in human bone marrow and serum.

Authors:  J A van Nieuwkoop; J Radl
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

4.  Plasma exchange combined with bortezomib-based chemotherapy is effective for early renal recovery in a patient with IgD-λ type multiple myeloma.

Authors:  Hiroyuki Ueda; Hideaki Kuno; Daisuke Takahashi; Ai Katsuma; Ai Kimura; Akio Nakashima; Junichiro Kato; Mamiko Momoki; Rie Ohba; Nobuaki Dobashi; Izumi Yamamoto; Tetsuya Kawamura; Yoichi Miyazaki; Takashi Yokoo
Journal:  CEN Case Rep       Date:  2020-01-23

5.  Efficacy and outcome of autologous transplantation in rare myelomas.

Authors:  Curly Morris; Mary Drake; Jane Apperley; Simona Iacobelli; Anja van Biezen; Bo Bjorkstrand; Hartmut Goldschmidt; Jean-Luc Harousseau; Gareth Morgan; Theo de Witte; Dietger Niederwieser; Gosta Gahrton
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

6.  IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy.

Authors:  Francesco Pisani; Maria Teresa Petrucci; Diana Giannarelli; Velia Bongarzoni; Marco Montanaro; Valerio De Stefano; Giacinto La Verde; Fabiana Gentilini; Anna Levi; Tommaso Za; Alessandro Moscetti; Luciana Annino; Maria Concetta Petti
Journal:  J Exp Clin Cancer Res       Date:  2012-03-01

7.  The normal counterpart of IgD myeloma cells in germinal center displays extensively mutated IgVH gene, Cmu-Cdelta switch, and lambda light chain expression.

Authors:  C Arpin; O de Bouteiller; D Razanajaona; I Fugier-Vivier; F Brière; J Banchereau; S Lebecque; Y J Liu
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

8.  "D" is for Dilemma.

Authors:  Pirkash Kumar; Carolina Borz-Baba; Sina Raissi
Journal:  Cureus       Date:  2019-09-16

9.  Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.

Authors:  Yong Pil Chong; Shin Kim; Ok Bae Ko; Ja Eun Koo; Danbi Lee; Sang Hyoung Park; Soo Jung Park; Daeho Lee; Sang We Kim; Cheolwon Suh
Journal:  J Korean Med Sci       Date:  2008-10       Impact factor: 2.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.